OTLK
Outlook Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.67
−1.37%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$0.70
From 52W high−72.81%
Volume2.78M
Market cap$163.52M
P/E (TTM)—
P/S (TTM)−140.6x
Div yield—
Key dataSep 18, 2026
Open
$0.70
From 52W high
−72.81%
Volume
2.78M
Market cap
$163.52M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.7x
P/E (TTM)
—
RSI (14)
42.4
MomentumView details →
1D Return
−1.37%
YTD Return
−56.99%
SummaryUpdated Jun 1, 2026
Outlook Therapeutics, Inc. (NASDAQ:OTLK) is a late-stage biopharmaceutical company founded in 2010 and headquartered in Iselin, New Jersey. Originally incorporated as Oncobiologics, Inc., the company rebranded to Outlook Therapeutics in November 2018 to reflect its strategic pivot toward ophthalmology. The company went public in 2016 and has evolved from a broader oncology focus to specialize exclusively in developing monoclonal antibody treatments for eye diseases, particularly retinal disorders that can cause blindness.
Similar companies
Latest newsMore news →
The U.S. Food and Drug Administration approved Outlook Therapeutics' LYTENAVA, according to CEO Bob Jahr.10d agoLawrence A. Kenyon departed as Chief Financial Officer, Treasurer and Corporate Secretary of Outlook Therapeutics, Inc. effective September 1, 2026, and Kevin Lundquist was appointed as his successor, effective the same date.24d agoOutlook Therapeutics plans to launch Lytenava in the U.S. by the end of 2026, following FDA approval.41d ago